252 related articles for article (PubMed ID: 10418752)
1. Perspectives for the treatment of hepatitis B virus infections.
De Clercq E
Int J Antimicrob Agents; 1999 Jul; 12(2):81-95. PubMed ID: 10418752
[TBL] [Abstract][Full Text] [Related]
2. Animal models for the study of HBV infection and the evaluation of new anti-HBV strategies.
Zoulim F; Berthillon P; Guerhier FL; Seigneres B; Germon S; Pichoud C; Cheng YC; Trepo C
J Gastroenterol Hepatol; 2002 Dec; 17 Suppl():S460-3. PubMed ID: 12534778
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses.
Seignères B; Pichoud C; Martin P; Furman P; Trépo C; Zoulim F
Hepatology; 2002 Sep; 36(3):710-22. PubMed ID: 12198665
[TBL] [Abstract][Full Text] [Related]
4. In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir.
Colledge D; Civitico G; Locarnini S; Shaw T
Antimicrob Agents Chemother; 2000 Mar; 44(3):551-60. PubMed ID: 10681317
[TBL] [Abstract][Full Text] [Related]
5. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance.
Ono SK; Kato N; Shiratori Y; Kato J; Goto T; Schinazi RF; Carrilho FJ; Omata M
J Clin Invest; 2001 Feb; 107(4):449-55. PubMed ID: 11181644
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir.
Ying C; De Clercq E; Nicholson W; Furman P; Neyts J
J Viral Hepat; 2000 Mar; 7(2):161-5. PubMed ID: 10760047
[TBL] [Abstract][Full Text] [Related]
7. Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation.
Yang L; Shi LP; Chen HJ; Tong XK; Wang GF; Zhang YM; Wang WL; Feng CL; He PL; Zhu FH; Hao YH; Wang BJ; Yang DL; Tang W; Nan FJ; Zuo JP
Acta Pharmacol Sin; 2014 Mar; 35(3):410-8. PubMed ID: 24487969
[TBL] [Abstract][Full Text] [Related]
8. Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model.
Seignères B; Martin P; Werle B; Schorr O; Jamard C; Rimsky L; Trépo C; Zoulim F
Antimicrob Agents Chemother; 2003 Jun; 47(6):1842-52. PubMed ID: 12760857
[TBL] [Abstract][Full Text] [Related]
9. Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans.
Korba BE; Cote P; Hornbuckle W; Tennant BC; Gerin JL
Hepatology; 2000 May; 31(5):1165-75. PubMed ID: 10796894
[TBL] [Abstract][Full Text] [Related]
10. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil.
Chin R; Shaw T; Torresi J; Sozzi V; Trautwein C; Bock T; Manns M; Isom H; Furman P; Locarnini S
Antimicrob Agents Chemother; 2001 Sep; 45(9):2495-501. PubMed ID: 11502520
[TBL] [Abstract][Full Text] [Related]
11. Clinical potential of emerging new agents in hepatitis B.
Farrell GC
Drugs; 2000 Oct; 60(4):701-10. PubMed ID: 11085196
[TBL] [Abstract][Full Text] [Related]
12. Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent.
Chu CK; Boudinot FD; Peek SF; Hong JH; Choi Y; Korba BE; Gerin JL; Cote PJ; Tennant BC; Cheng YC
Antivir Ther; 1998; 3(Suppl 3):113-21. PubMed ID: 10726061
[TBL] [Abstract][Full Text] [Related]
13. In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.
Jacquard AC; Brunelle MN; Pichoud C; Durantel D; Carrouée-Durantel S; Trepo C; Zoulim F
Antimicrob Agents Chemother; 2006 Mar; 50(3):955-61. PubMed ID: 16495257
[TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
15. Anti-hepatitis B virus activity of α-DDB-FNCG, a novel nucleoside-biphenyldicarboxylate compound in vitro and in vivo.
Yang Q; Zhao X; Yu W; He W; Fang X; Zang L; Wan N; Wang Q; Zheng L; Chang J
J Pharmacol Sci; 2014; 126(3):208-15. PubMed ID: 25409748
[TBL] [Abstract][Full Text] [Related]
16. Antiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus.
Le Guerhier F; Pichoud C; Jamard C; Guerret S; Chevallier M; Peyrol S; Hantz O; King I; Trépo C; Cheng YC; Zoulim F
Antimicrob Agents Chemother; 2001 Apr; 45(4):1065-77. PubMed ID: 11257017
[TBL] [Abstract][Full Text] [Related]
17. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).
Das K; Xiong X; Yang H; Westland CE; Gibbs CS; Sarafianos SG; Arnold E
J Virol; 2001 May; 75(10):4771-9. PubMed ID: 11312349
[TBL] [Abstract][Full Text] [Related]
18. Enhanced antiviral benefit of combination therapy with lamivudine and famciclovir against WHV replication in chronic WHV carrier woodchucks.
Korba BE; Cote P; Hornbuckle W; Schinazi R; Gerin JL; Tennant BC
Antiviral Res; 2000 Jan; 45(1):19-32. PubMed ID: 10774587
[TBL] [Abstract][Full Text] [Related]
19. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation.
Delaney WE; Locarnini S; Shaw T
Antivir Chem Chemother; 2001 Jan; 12(1):1-35. PubMed ID: 11437320
[TBL] [Abstract][Full Text] [Related]
20. Anti-HBV effect of individual traditional Chinese herbal medicine in vitro and in vivo: an analytic review.
Chen Y; Zhu J
J Viral Hepat; 2013 Jul; 20(7):445-52. PubMed ID: 23730837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
